24.31 USD
+0.57 (+2.4%)
24.4447 USD
+0.13 (+0.55%)
CPRX gets a fundamental rating of 8 out of 10. The analysis compared the fundamentals against 530 industry peers in the Biotechnology industry. CPRX scores excellent points on both the profitability and health parts. This is a solid base for a good stock. CPRX has both an excellent growth and valuation score. This means it is growing and it is still cheap. This is a rare combination! With these ratings, CPRX could be worth investigating further for value and growth and quality investing!.
1. Profitability
1.1 Basic Checks
In the past year CPRX was profitable.
In the past year CPRX had a positive cash flow from operations.
Each year in the past 5 years CPRX has been profitable.
In the past 5 years CPRX always reported a positive cash flow from operatings.
1.2 Ratios
CPRX has a better Return On Assets (20.69%) than 96.98% of its industry peers.
The Return On Equity of CPRX (23.65%) is better than 96.79% of its industry peers.
The Return On Invested Capital of CPRX (21.23%) is better than 97.92% of its industry peers.
The Average Return On Invested Capital over the past 3 years for CPRX is above the industry average of 18.22%.
The last Return On Invested Capital (21.23%) for CPRX is above the 3 year average (20.37%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.69% | ||
| ROE | 23.65% | ||
| ROIC | 21.23% |
ROA(3y)18.85%
ROA(5y)22.43%
ROE(3y)22.87%
ROE(5y)26.38%
ROIC(3y)20.37%
ROIC(5y)19.67%
1.3 Margins
The Profit Margin of CPRX (37.64%) is better than 96.60% of its industry peers.
In the last couple of years the Profit Margin of CPRX has remained more or less at the same level.
With an excellent Operating Margin value of 44.78%, CPRX belongs to the best of the industry, outperforming 99.25% of the companies in the same industry.
In the last couple of years the Operating Margin of CPRX has grown nicely.
CPRX's Gross Margin of 85.68% is amongst the best of the industry. CPRX outperforms 88.49% of its industry peers.
In the last couple of years the Gross Margin of CPRX has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 44.78% | ||
| PM (TTM) | 37.64% | ||
| GM | 85.68% |
OM growth 3Y2.16%
OM growth 5Y5%
PM growth 3Y5.91%
PM growth 5Y1.34%
GM growth 3Y0.61%
GM growth 5Y0.11%
2. Health
2.1 Basic Checks
CPRX has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
CPRX has more shares outstanding than it did 1 year ago.
CPRX has more shares outstanding than it did 5 years ago.
CPRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
CPRX has an Altman-Z score of 16.43. This indicates that CPRX is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 16.43, CPRX belongs to the top of the industry, outperforming 86.79% of the companies in the same industry.
There is no outstanding debt for CPRX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 16.43 |
ROIC/WACC2.41
WACC8.81%
2.3 Liquidity
CPRX has a Current Ratio of 6.62. This indicates that CPRX is financially healthy and has no problem in meeting its short term obligations.
CPRX has a Current ratio of 6.62. This is in the better half of the industry: CPRX outperforms 67.55% of its industry peers.
A Quick Ratio of 6.40 indicates that CPRX has no problem at all paying its short term obligations.
CPRX's Quick ratio of 6.40 is fine compared to the rest of the industry. CPRX outperforms 66.23% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.62 | ||
| Quick Ratio | 6.4 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 45.76% over the past year.
CPRX shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 34.29% yearly.
Looking at the last year, CPRX shows a very strong growth in Revenue. The Revenue has grown by 25.56%.
The Revenue has been growing by 36.89% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)45.76%
EPS 3Y52.41%
EPS 5Y34.29%
EPS Q2Q%20%
Revenue 1Y (TTM)25.56%
Revenue growth 3Y51.72%
Revenue growth 5Y36.89%
Sales Q2Q%15.31%
3.2 Future
The Earnings Per Share is expected to grow by 26.80% on average over the next years. This is a very strong growth
Based on estimates for the next years, CPRX will show a quite strong growth in Revenue. The Revenue will grow by 11.21% on average per year.
EPS Next Y22.87%
EPS Next 2Y22.01%
EPS Next 3Y12.53%
EPS Next 5Y26.8%
Revenue Next Year19.37%
Revenue Next 2Y13.12%
Revenue Next 3Y11.23%
Revenue Next 5Y11.21%
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 14.13 indicates a correct valuation of CPRX.
Compared to the rest of the industry, the Price/Earnings ratio of CPRX indicates a rather cheap valuation: CPRX is cheaper than 96.04% of the companies listed in the same industry.
The average S&P500 Price/Earnings ratio is at 26.61. CPRX is valued slightly cheaper when compared to this.
Based on the Price/Forward Earnings ratio of 12.47, the valuation of CPRX can be described as correct.
Based on the Price/Forward Earnings ratio, CPRX is valued cheaply inside the industry as 97.92% of the companies are valued more expensively.
When comparing the Price/Forward Earnings ratio of CPRX to the average of the S&P500 Index (24.01), we can say CPRX is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.13 | ||
| Fwd PE | 12.47 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of CPRX indicates a rather cheap valuation: CPRX is cheaper than 97.92% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, CPRX is valued cheaper than 97.55% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 12.73 | ||
| EV/EBITDA | 7.74 |
4.3 Compensation for Growth
CPRX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The excellent profitability rating of CPRX may justify a higher PE ratio.
CPRX's earnings are expected to grow with 12.53% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.62
PEG (5Y)0.41
EPS Next 2Y22.01%
EPS Next 3Y12.53%
5. Dividend
5.1 Amount
No dividends for CPRX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:CPRX (12/22/2025, 8:00:00 PM)
After market: 24.4447 +0.13 (+0.55%)24.31
+0.57 (+2.4%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners87.01%
Inst Owner Change1.44%
Ins Owners5.56%
Ins Owner Change1.93%
Market Cap2.99B
Revenue(TTM)578.20M
Net Income(TTM)217.63M
Analysts88.57
Price Target35.19 (44.76%)
Short Float %6.87%
Short Ratio6.09
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)14.08%
Min EPS beat(2)4.13%
Max EPS beat(2)24.03%
EPS beat(4)4
Avg EPS beat(4)21.33%
Min EPS beat(4)4.13%
Max EPS beat(4)29.76%
EPS beat(8)8
Avg EPS beat(8)18.46%
EPS beat(12)11
Avg EPS beat(12)14.56%
EPS beat(16)13
Avg EPS beat(16)9.74%
Revenue beat(2)2
Avg Revenue beat(2)4.27%
Min Revenue beat(2)2.19%
Max Revenue beat(2)6.34%
Revenue beat(4)4
Avg Revenue beat(4)4.39%
Min Revenue beat(4)2.19%
Max Revenue beat(4)6.34%
Revenue beat(8)7
Avg Revenue beat(8)3.51%
Revenue beat(12)11
Avg Revenue beat(12)3.34%
Revenue beat(16)13
Avg Revenue beat(16)2.97%
PT rev (1m)1.47%
PT rev (3m)1.47%
EPS NQ rev (1m)6.21%
EPS NQ rev (3m)14.07%
EPS NY rev (1m)8.23%
EPS NY rev (3m)8.38%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)3.31%
Revenue NY rev (1m)2.82%
Revenue NY rev (3m)2.88%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.13 | ||
| Fwd PE | 12.47 | ||
| P/S | 5.17 | ||
| P/FCF | 12.73 | ||
| P/OCF | 12.73 | ||
| P/B | 3.25 | ||
| P/tB | 3.77 | ||
| EV/EBITDA | 7.74 |
EPS(TTM)1.72
EY7.08%
EPS(NY)1.95
Fwd EY8.02%
FCF(TTM)1.91
FCFY7.85%
OCF(TTM)1.91
OCFY7.86%
SpS4.7
BVpS7.49
TBVpS6.44
PEG (NY)0.62
PEG (5Y)0.41
Graham Number17.02
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.69% | ||
| ROE | 23.65% | ||
| ROCE | 28.06% | ||
| ROIC | 21.23% | ||
| ROICexc | 84.1% | ||
| ROICexgc | 187.79% | ||
| OM | 44.78% | ||
| PM (TTM) | 37.64% | ||
| GM | 85.68% | ||
| FCFM | 40.59% |
ROA(3y)18.85%
ROA(5y)22.43%
ROE(3y)22.87%
ROE(5y)26.38%
ROIC(3y)20.37%
ROIC(5y)19.67%
ROICexc(3y)162.63%
ROICexc(5y)159.51%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)26.92%
ROCE(5y)25.99%
ROICexgc growth 3Y8.72%
ROICexgc growth 5YN/A
ROICexc growth 3Y-30.16%
ROICexc growth 5YN/A
OM growth 3Y2.16%
OM growth 5Y5%
PM growth 3Y5.91%
PM growth 5Y1.34%
GM growth 3Y0.61%
GM growth 5Y0.11%
F-Score6
Asset Turnover0.55
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 0.31% | ||
| Cap/Sales | 0.02% | ||
| Interest Coverage | 593.88 | ||
| Cash Conversion | 79.12% | ||
| Profit Quality | 107.83% | ||
| Current Ratio | 6.62 | ||
| Quick Ratio | 6.4 | ||
| Altman-Z | 16.43 |
F-Score6
WACC8.81%
ROIC/WACC2.41
Cap/Depr(3y)0.72%
Cap/Depr(5y)100.44%
Cap/Sales(3y)0.06%
Cap/Sales(5y)0.18%
Profit Quality(3y)162.12%
Profit Quality(5y)139.35%
High Growth Momentum
Growth
EPS 1Y (TTM)45.76%
EPS 3Y52.41%
EPS 5Y34.29%
EPS Q2Q%20%
EPS Next Y22.87%
EPS Next 2Y22.01%
EPS Next 3Y12.53%
EPS Next 5Y26.8%
Revenue 1Y (TTM)25.56%
Revenue growth 3Y51.72%
Revenue growth 5Y36.89%
Sales Q2Q%15.31%
Revenue Next Year19.37%
Revenue Next 2Y13.12%
Revenue Next 3Y11.23%
Revenue Next 5Y11.21%
EBIT growth 1Y48.97%
EBIT growth 3Y55%
EBIT growth 5Y43.74%
EBIT Next Year76.08%
EBIT Next 3Y25.59%
EBIT Next 5YN/A
FCF growth 1Y83.47%
FCF growth 3Y59.11%
FCF growth 5Y47.22%
OCF growth 1Y83.42%
OCF growth 3Y58.35%
OCF growth 5Y47.28%
CATALYST PHARMACEUTICALS INC / CPRX FAQ
What is the ChartMill fundamental rating of CATALYST PHARMACEUTICALS INC (CPRX) stock?
ChartMill assigns a fundamental rating of 8 / 10 to CPRX.
What is the valuation status of CATALYST PHARMACEUTICALS INC (CPRX) stock?
ChartMill assigns a valuation rating of 8 / 10 to CATALYST PHARMACEUTICALS INC (CPRX). This can be considered as Undervalued.
Can you provide the profitability details for CATALYST PHARMACEUTICALS INC?
CATALYST PHARMACEUTICALS INC (CPRX) has a profitability rating of 9 / 10.
What is the financial health of CATALYST PHARMACEUTICALS INC (CPRX) stock?
The financial health rating of CATALYST PHARMACEUTICALS INC (CPRX) is 8 / 10.